
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>ACG Clinical Guideline: Management of Irritable Bowel Syndrome</title>
<style>

<style>
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #f0f4ff, #fafafa);
    color: #2c2c2c;
    padding: 40px;
}

/* Mindmap container */
.mindmap {
    max-width: 900px;
    margin: auto;
    font-size: 16px;
    line-height: 1.7;
}

.mindmap ul {
    margin: 0.5em 0 1em 1em;
    padding-left: 1.5em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #a855f7; /* prettier bullets */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}


/* Collapsible sections */
.mindmap details {
    border-left: 4px solid #8b5cf6;
    background: #ffffff;
    margin: 15px 0;
    padding: 16px 20px;
    border-radius: 16px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.12);
    transition: all 0.3s ease;
    position: relative;
}

/* Hover glow */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.2);
    background: linear-gradient(135deg, #ffffff, #f3f0ff);
}

/* Summary styling */
.mindmap summary {
    cursor: pointer;
    font-size: 1.15em;
    font-weight: 600;
    list-style: none;
    position: relative;
    padding-left: 28px;
    color: #4c1d95;
}

/* Custom arrow */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Titles */
.mindmap summary strong {
    display: block;
    font-size: 1.3em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Description bullets */
.mindmap ul {
    padding-left: 22px;
    margin-top: 10px;
    margin-bottom: 12px;
}

.mindmap li {
    margin-bottom: 6px;
    font-size: 0.97em;
    color: #444;
    list-style-type: disc;
    position: relative;
    padding-left: 4px;
}

/* Nesting indent style */
.mindmap details > div > details {
    margin-left: 20px;
    border-color: #a855f7;
    background: #f9f5ff;
}

/* Fade-in effect */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* Description box */
.mindmap .desc-box {
    background: #fdfcff;
    border: 1px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 4px 6px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.06);
    transition: background 0.3s ease;
}

.mindmap .desc-box:hover {
    background: #f9f4ff;
}


button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 1em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease;
}
button:hover {
    background-color: #6b21a8;
}


@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}


#level-controls button {
    background-color: rgba(124, 58, 237, 0.7); /* semi-transparent purple */
    color: white;
    border: none;
    padding: 8px 14px;
    margin: 0 6px;
    font-size: 1em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s;
}

#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.85); /* slightly darker on hover */
    transform: scale(1.05);
}

#level-controls {
    position: fixed;
    bottom: 20px;
    left: 50%;
    transform: translateX(-50%);
    background: rgba(124, 58, 237, 0.1);
    padding: 8px 14px;
    border-radius: 12px;
    box-shadow: 0 4px 10px rgba(0, 0, 0, 0.1);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move; /* shows move cursor */
}

</style>




</style>
</head>
<body>
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="setMindmapLevel(1)">Level 1</button>
    <button onclick="setMindmapLevel(2)">Level 2</button>
    <button onclick="setMindmapLevel(3)">Level 3</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>ACG Clinical Guideline: Management of Irritable Bowel Syndrome</strong></summary>
            <div>
                <ul><li>Journal: The American Journal of Gastroenterology</li><li>Publication Date: January 2021 (published online December 14, 2020)</li><li>Authors: Brian E. Lacy, et al.</li><li>Methodology: Grading of Recommendations, Assessment, Development, and Evaluation (GRADE).</li></ul>
                
        <details>
            <summary><strong>Knowledge Test</strong></summary>
            <div>
                <ul><li>1. What is the Number Needed to Treat (NNT) with soluble fiber (ispaghula) to see an improvement in global IBS symptoms?</li><li>2. In patients with IBS-D, what percentage are estimated to have bile acid malabsorption (BAM) based on SeHCAT testing?</li><li>3. What is the recommended starting dose for amitriptyline when used as a neuromodulator for IBS?</li><li>4. What is the pooled prevalence of post-infection IBS following a GI infection?</li><li>5. For which specific patient population is alosetron recommended, and what is the primary risk associated with its use?</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>IBS: Introduction &amp; Definition</strong></summary>
            <div>
                <ul><li>IBS is a chronic, highly prevalent disorder of gut-brain interaction.</li><li>Characterized by recurrent abdominal pain &amp; disordered defecation.</li><li>Prevalence in US, UK, Canada ≈ 4.4%–4.8%; most common in women &amp; individuals &lt; 50 years.</li></ul>
                
        <details>
            <summary><strong>Rome IV Diagnostic Criteria</strong></summary>
            <div>
                <ul><li>Recurrent abdominal pain ≥ 1 day/week in the last 3 months.</li><li>Associated w/ ≥ 2 of the following:</li><li>- Related to defecation</li><li>- Associated w/ a change in stool frequency</li><li>- Associated w/ a change in stool form (appearance)</li></ul>
                
        <details>
            <summary><strong>Timing Criteria</strong></summary>
            <div>
                <ul><li>Criteria must be fulfilled for the last 3 months.</li><li>Symptom onset must be ≥ 6 months before diagnosis.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Patient Impact</strong></summary>
            <div>
                <ul><li>Significantly reduces quality of life (QoL).</li><li>Majority of patients would give up 10–15 years of life for an instant cure.</li><li>Patients would accept a median 1% risk of sudden death for a curative medication.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Economic Burden</strong></summary>
            <div>
                <ul><li>Direct medical costs in the US estimated at $1.5–$10 billion per year (excluding medications).</li><li>High healthcare resource utilization &amp; unnecessary testing contribute to costs.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Diagnostic Strategies</strong></summary>
            <div>
                <ul><li>Focuses on key questions regarding diagnostic testing in patients with suspected IBS.</li></ul>
                
        <details>
            <summary><strong>1. Celiac Disease (CD) Screening</strong></summary>
            <div>
                <ul><li>Recommendation: Perform serologic testing to rule out CD in patients w/ IBS &amp; diarrhea symptoms.</li><li>Strength: Strong recommendation.</li><li>Evidence Quality: Moderate.</li></ul>
                
        <details>
            <summary><strong>Rationale &amp; Prevalence</strong></summary>
            <div>
                <ul><li>CD symptoms (pain, bloating, altered bowels) can mimic IBS.</li><li>Prevalence of biopsy-proven CD in patients w/ IBS symptoms: 3.3% (95% CI 2.3%–4.5%).</li><li>Pooled Odds Ratio (OR) for biopsy-proven CD in IBS vs controls: 4.48 (95% CI 2.33–4.60).</li></ul>
                
        <details>
            <summary><strong>Prevalence by IBS Subtype</strong></summary>
            <div>
                <ul><li>Highest prevalence in IBS-D: 5.7% (EMA or tTG positive).</li><li>IBS-M: 3.4%.</li><li>IBS-C: 2.1% (lowest).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Screening Recommendations</strong></summary>
            <div>
                <ul><li>Recommended test: Immunoglobulin A (IgA) tissue transglutaminase (tTG).</li><li>Also check quantitative IgA level to rule out IgA deficiency.</li><li>If endoscopy is performed: obtain 6 duodenal biopsies, including the bulb.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Clinical Importance</strong></summary>
            <div>
                <ul><li>Untreated CD → significant consequences (e.g., neuropsychiatric disease, other autoimmune diseases, GI malignancies).</li><li>Early diagnosis is cost-effective &amp; allows for highly effective treatment.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>2. Inflammatory Bowel Disease (IBD) Exclusion</strong></summary>
            <div>
                <ul><li>Recommendation: Check fecal calprotectin (or fecal lactoferrin) &amp; C-reactive protein (CRP) in patients w/o alarm features &amp; suspected IBS-D to rule out IBD.</li><li>Strength: Strong recommendation.</li><li>Evidence Quality: Moderate for CRP/fCal; Very low for fecal lactoferrin.</li></ul>
                
        <details>
            <summary><strong>Rationale</strong></summary>
            <div>
                <ul><li>Symptoms alone cannot always distinguish IBS-D from IBD.</li><li>Pre-test probability of IBD in IBS is low (0.5%–1.2%), but incidence is 2.6–5 times higher than controls after 5 years of symptoms.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Biomarker Performance</strong></summary>
            <div>
                <ul><li>CRP: A level ≤0.5 mg/dL yields a 1% probability of IBD.</li><li>Fecal Calprotectin (fCal): Sensitivity 93%, Specificity 96% for IBD vs endoscopy.</li><li>Fecal Lactoferrin (FL): Sensitivity 67%–86%, Specificity 96%–100% for active IBD vs IBS.</li></ul>
                
        <details>
            <summary><strong>Key Point</strong></summary>
            <div>
                <ul><li>Negative Predictive Value (NPV) of fCal is superior to CRP &amp; ESR.</li><li>These tests are for ruling out IBD, not for ruling in IBS.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>3. Enteric Pathogen Testing</strong></summary>
            <div>
                <ul><li>Recommendation: Against routine stool testing for enteric pathogens in all patients w/ IBS.</li><li>Strength: Conditional recommendation.</li><li>Evidence Quality: Low.</li></ul>
                
        <details>
            <summary><strong>Post-Infection IBS (PI-IBS)</strong></summary>
            <div>
                <ul><li>IBS can arise after bacterial, viral, or parasitic GI infections.</li><li>Estimated pooled prevalence of PI-IBS: 11% (95% CI 8.2–15.8).</li><li>Risk is 4.2 times higher in exposed vs non-exposed individuals.</li></ul>
                
        <details>
            <summary><strong>Risk Factors for PI-IBS</strong></summary>
            <div>
                <ul><li>Female gender.</li><li>Antibiotic exposure during infection.</li><li>History of anxiety or depression.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Role of Giardia</strong></summary>
            <div>
                <ul><li>Giardia is the most common parasitic pathogen in the US associated w/ PI-IBS.</li><li>Relative risk of developing IBS after Giardiasis: 3.4 (95% CI 2.9–3.9).</li><li>Prevalence of any parasitic infection in IBS is low (&lt;2%).</li></ul>
                
        <details>
            <summary><strong>When to Test for Giardia</strong></summary>
            <div>
                <ul><li>Testing is indicated only in patients w/ specific risk factors:</li><li>- Travel to endemic areas</li><li>- Poor water quality exposure (camping, hiking)</li><li>- Daycare exposure</li><li>- Close contact w/ infected person</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>4. Colonoscopy Utility</strong></summary>
            <div>
                <ul><li>Recommendation: Against routine colonoscopy in patients w/ IBS symptoms &lt; 45 years old w/o warning signs.</li><li>Strength: Conditional recommendation.</li><li>Evidence Quality: Low.</li></ul>
                
        <details>
            <summary><strong>Alarm Features</strong></summary>
            <div>
                <ul><li>Warrant consideration for colonoscopy:</li><li>- Hematochezia, melena</li><li>- Unintentional weight loss</li><li>- Older age of onset</li><li>- Family history of IBD, colon cancer, or other significant GI disease.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Diagnostic Yield</strong></summary>
            <div>
                <ul><li>In patients w/o alarm features, yield is low.</li><li>Common findings: hemorrhoids, diverticulosis, polyps.</li><li>Rate of polyps may be lower in IBS vs controls (7.7% vs 26.1%).</li></ul>
                
        <details>
            <summary><strong>Special Considerations</strong></summary>
            <div>
                <ul><li>Microscopic colitis: Consider colonoscopy in women &gt; 60 years w/ new-onset, intense diarrhea.</li><li>Colon cancer screening: Should be performed based on age-appropriate guidelines, independent of IBS symptoms.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>5 &amp; 6. Positive vs. Exclusionary Diagnostic Strategy</strong></summary>
            <div>
                <ul><li>A positive diagnostic strategy involves a careful history, physical exam, use of standard criteria (e.g., Rome IV), &amp; limited diagnostic tests.</li></ul>
                
        <details>
            <summary><strong>Improve Time to Therapy</strong></summary>
            <div>
                <ul><li>Recommendation: Use a positive diagnostic strategy to improve time to initiate appropriate therapy.</li><li>Strength: Consensus recommendation (unable to assess using GRADE).</li><li>Rationale: Reduces delay, engages patients in shared decision-making, allows earlier access to evidence-based therapies.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Improve Cost-Effectiveness</strong></summary>
            <div>
                <ul><li>Recommendation: Use a positive diagnostic strategy to improve cost-effectiveness.</li><li>Strength: Strong recommendation.</li><li>Evidence Quality: High.</li></ul>
                
        <details>
            <summary><strong>Cost Data</strong></summary>
            <div>
                <ul><li>Providers using an &#x27;exclusion&#x27; strategy order nearly 2x the tests &amp; consume $400 more per patient.</li><li>In one study, a positive strategy was ~40% cheaper ($3,160 vs $5,075 annually) w/ no difference in symptoms or satisfaction.</li><li>In IBS-D, ~80% of healthcare costs in the first 2 years are associated w/ a diagnosis of exclusion approach.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>7. IBS Subtype Categorization</strong></summary>
            <div>
                <ul><li>Recommendation: Categorizing patients by accurate IBS subtype improves patient therapy.</li><li>Strength: Consensus recommendation (unable to assess using GRADE).</li><li>Rationale: Pharmacological therapies usually target specific subtypes (IBS-D, IBS-C).</li></ul>
                
        <details>
            <summary><strong>How to Subtype</strong></summary>
            <div>
                <ul><li>1. Use Bristol Stool Form Scale (BSFS).</li><li>2. Assess predominant stool consistency only on days w/ abnormal bowel movements (off therapy).</li><li>3. Apply Rome IV criteria based on % of abnormal BMs.</li></ul>
                
        <details>
            <summary><strong>Rome IV Subtype Definitions</strong></summary>
            <div>
                <ul><li>IBS-C: &gt;25% BSFS 1-2 &amp; &lt;25% BSFS 6-7.</li><li>IBS-D: &gt;25% BSFS 6-7 &amp; &lt;25% BSFS 1-2.</li><li>IBS-M: &gt;25% BSFS 1-2 &amp; &gt;25% BSFS 6-7.</li><li>IBS-U: Cannot be determined.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Subtype Fluctuation</strong></summary>
            <div>
                <ul><li>&gt;50% of patients change predominant subtype over a 1-year period.</li><li>Clarification of subtype should be performed routinely.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>8. Food Allergy &amp; Sensitivity Testing</strong></summary>
            <div>
                <ul><li>Recommendation: Do not test for food allergies &amp; food sensitivities in all patients w/ IBS unless there are reproducible symptoms concerning for a food allergy.</li><li>Strength: Consensus recommendation (unable to assess using GRADE).</li></ul>
                
        <details>
            <summary><strong>Food Allergy vs. Intolerance</strong></summary>
            <div>
                <ul><li>Food Allergy: Immune-mediated (IgE, non-IgE, or mixed). Uncommon in adults (1-3%). Patients w/ IBS are not more likely to have them.</li><li>Food Intolerance/Sensitivity: Not immune-mediated. More common in IBS (up to 50% report adverse food reactions).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Testing Limitations</strong></summary>
            <div>
                <ul><li>Skin prick test: Positive only 50% of the time in true food allergies.</li><li>Serum IgE: Low sensitivity; can miss up to 25% of significant reactions.</li><li>Serum IgG panels: Not validated &amp; not recommended.</li><li>Indiscriminate testing → many false positives.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>9. Anorectal Physiology Testing</strong></summary>
            <div>
                <ul><li>Recommendation: Perform anorectal physiology testing in patients w/ IBS &amp; symptoms suggestive of a pelvic floor disorder and/or refractory constipation.</li><li>Strength: Consensus recommendation (unable to assess using GRADE).</li></ul>
                
        <details>
            <summary><strong>Prevalence &amp; Symptoms</strong></summary>
            <div>
                <ul><li>Anorectal dysfunction occurs in all IBS subtypes; prevalence up to 40% in tertiary care.</li><li>Symptoms alone cannot distinguish IBS from dyssynergic defecation (DD).</li><li>Symptoms suggesting DD: straining, incomplete evacuation, digital disimpaction.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Diagnostic Tests</strong></summary>
            <div>
                <ul><li>Anorectal manometry (ARM).</li><li>Balloon expulsion test (BET).</li><li>Defecography.</li><li>Diagnosis of DD requires abnormalities on 2 of 3 tests.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Clinical Utility</strong></summary>
            <div>
                <ul><li>Identifies patients who may benefit from biofeedback therapy.</li><li>Biofeedback can improve both bowel symptoms &amp; abdominal pain in IBS patients w/ DD.</li><li>44% of female patients w/ IBS-C have prolonged BET, suggesting DD.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Management &amp; Treatment Strategies</strong></summary>
            <div>
                <ul><li>Focuses on therapeutic options for patients with IBS, including dietary, pharmacologic, and psychological interventions.</li></ul>
                
        <details>
            <summary><strong>Dietary &amp; Lifestyle Interventions</strong></summary>
            <div>
                <ul><li>Recommendations on dietary modifications for managing IBS symptoms.</li></ul>
                
        <details>
            <summary><strong>10. Low FODMAP Diet</strong></summary>
            <div>
                <ul><li>Recommendation: A limited trial of a low FODMAP diet to improve global IBS symptoms.</li><li>Strength: Conditional recommendation.</li><li>Evidence Quality: Very low.</li></ul>
                
        <details>
            <summary><strong>Mechanism &amp; Efficacy</strong></summary>
            <div>
                <ul><li>FODMAPs → ↑ GI water secretion &amp; fermentation → luminal distension &amp; symptoms.</li><li>Meta-analysis showed significant reduction in global IBS symptoms (Risk Ratio 0.69; 95% CI 0.54–0.88).</li><li>Benefits noted for abdominal pain &amp; bloating.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Implementation (3 Phases)</strong></summary>
            <div>
                <ul><li>1. Substitution: Replace high FODMAP foods w/ low FODMAP choices (2-6 weeks).</li><li>2. Reintroduction: Gradual reintroduction of individual FODMAPs to determine sensitivities.</li><li>3. Personalization: Liberalize diet based on individual tolerance.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Clinical Considerations</strong></summary>
            <div>
                <ul><li>Requires proper patient instruction, ideally by a trained GI dietitian.</li><li>Long-term over-restriction may lead to micronutrient deficiencies.</li><li>Need for high-quality, long-term data on efficacy, adherence, &amp; harms.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>11. Fiber Supplementation</strong></summary>
            <div>
                <ul><li>Recommendation: Use soluble, but not insoluble, fiber to treat global IBS symptoms.</li><li>Strength: Strong recommendation.</li><li>Evidence Quality: Moderate.</li></ul>
                
        <details>
            <summary><strong>Types of Fiber</strong></summary>
            <div>
                <ul><li>Soluble fiber: Psyllium (ispaghula), oat bran, barley, beans.</li><li>Insoluble fiber: Wheat bran, whole grains.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Efficacy</strong></summary>
            <div>
                <ul><li>Soluble fiber (ispaghula): Showed significant benefit for IBS symptoms (RR of not improving = 0.83).</li><li>Number Needed to Treat (NNT) = 7 (95% CI 4–25).</li><li>Insoluble fiber (bran): Provided no significant benefit.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Adverse Events</strong></summary>
            <div>
                <ul><li>AEs reported in 36% of patients on fiber vs 25.1% on placebo (not statistically significant).</li><li>Fibers that ferment in the colon can aggravate bloating &amp; flatulence.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Pharmacotherapy - General &amp; Symptom-Based</strong></summary>
            <div>
                <ul><li>Medications used for global IBS symptoms, not specific to one subtype.</li></ul>
                
        <details>
            <summary><strong>12. Antispasmodics (US Market)</strong></summary>
            <div>
                <ul><li>Recommendation: Against the use of antispasmodics currently available in the US for global IBS symptoms.</li><li>Strength: Conditional recommendation.</li><li>Evidence Quality: Low.</li></ul>
                
        <details>
            <summary><strong>Available Agents &amp; Evidence</strong></summary>
            <div>
                <ul><li>Dicyclomine: 2 small, older trials w/ methodological flaws; showed some benefit but high side effect rates (69%).</li><li>Hyoscyamine: 1 small trial; response comparable to placebo w/ significantly higher AEs (87% vs 7%).</li><li>Hyoscine (Scopolamine): 3 trials outside US w/ mixed results; one showed benefit (76% vs 64% placebo) but data is weak.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Conclusion</strong></summary>
            <div>
                <ul><li>Data is decades-old, of poor quality, w/ small sample sizes &amp; non-standardized criteria.</li><li>Side effects are common, especially in the elderly.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>13. Peppermint Oil</strong></summary>
            <div>
                <ul><li>Recommendation: Suggest the use of peppermint to provide relief of global IBS symptoms.</li><li>Strength: Conditional recommendation.</li><li>Evidence Quality: Low.</li></ul>
                
        <details>
            <summary><strong>Mechanism &amp; Efficacy</strong></summary>
            <div>
                <ul><li>Mechanism: L-menthol blocks calcium channels → smooth muscle relaxation. Also modulates visceral sensation &amp; has antimicrobial effects.</li><li>Meta-analysis (12 RCTs): RR for overall symptom improvement was 2.39 (95% CI 1.93–2.97) vs placebo.</li><li>NNT = 3 for overall symptoms; NNT = 4 for abdominal pain.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Safety &amp; Formulation</strong></summary>
            <div>
                <ul><li>AEs similar to placebo (9.3% vs 6.1%).</li><li>Heartburn can occur; enteric-coated formulations may mitigate this.</li><li>Only a small number of commercial supplements have been rigorously tested.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>14. Probiotics</strong></summary>
            <div>
                <ul><li>Recommendation: Suggest against probiotics for the treatment of global IBS symptoms.</li><li>Strength: Conditional recommendation.</li><li>Evidence Quality: Very low.</li></ul>
                
        <details>
            <summary><strong>Evidence Challenges</strong></summary>
            <div>
                <ul><li>Myriad of different products (single vs. multi-strain).</li><li>Studies are small, single-center, &amp; lack rigorous endpoints.</li><li>Meta-analyses are difficult to interpret due to significant heterogeneity.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Meta-Analysis Findings</strong></summary>
            <div>
                <ul><li>Combination probiotics showed a significant pooled effect (RR 0.79), but w/ high heterogeneity &amp; publication bias.</li><li>Single species (Lactobacillus, Bifidobacterium, Saccharomyces) did not show significant pooled benefit.</li><li>No category of probiotic showed benefit for bloating.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>23. Tricyclic Antidepressants (TCAs)</strong></summary>
            <div>
                <ul><li>Recommendation: Use TCAs to treat global symptoms of IBS.</li><li>Strength: Strong recommendation.</li><li>Evidence Quality: Moderate.</li></ul>
                
        <details>
            <summary><strong>Mechanism &amp; Efficacy</strong></summary>
            <div>
                <ul><li>Act as neuromodulators, improving visceral &amp; central pain.</li><li>Anticholinergic effects can slow GI transit, helping w/ diarrhea.</li><li>RR of symptoms not improving = 0.65 (95% CI 0.55–0.77) vs placebo.</li><li>NNT = 4.5 (95% CI 3.5–7).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Dosing &amp; Agent Selection</strong></summary>
            <div>
                <ul><li>Start low &amp; titrate slowly (e.g., amitriptyline or desipramine 10 mg).</li><li>Secondary amines (desipramine, nortriptyline): less sedation/constipation.</li><li>Tertiary amines (amitriptyline, imipramine): more antihistaminic/anticholinergic effects.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Safety &amp; Adverse Events</strong></summary>
            <div>
                <ul><li>AEs occur at a greater rate than placebo (RR 1.59).</li><li>Common AEs: dry mouth (36%), drowsiness, constipation (23%), insomnia (24%).</li><li>NNH = 9 (for any AE); NNH = 18 (for AEs prompting discontinuation).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Pharmacotherapy - IBS with Constipation (IBS-C)</strong></summary>
            <div>
                <ul><li>Medications specifically evaluated for IBS-C.</li></ul>
                
        <details>
            <summary><strong>15. Polyethylene Glycol (PEG)</strong></summary>
            <div>
                <ul><li>Recommendation: Suggest against PEG products to relieve global IBS symptoms in IBS-C.</li><li>Strength: Conditional recommendation.</li><li>Evidence Quality: Low.</li></ul>
                
        <details>
            <summary><strong>Rationale</strong></summary>
            <div>
                <ul><li>PEG is an effective osmotic laxative for chronic constipation (NNT=3).</li><li>However, RCTs have failed to show it improves overall symptoms or pain in IBS-C.</li><li>It improves stool frequency &amp; consistency, but not the key symptom of abdominal pain.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>16. Chloride Channel Activators (Lubiprostone)</strong></summary>
            <div>
                <ul><li>Recommendation: Use chloride channel activators to treat global IBS-C symptoms.</li><li>Strength: Strong recommendation.</li><li>Evidence Quality: Moderate.</li></ul>
                
        <details>
            <summary><strong>Mechanism &amp; Efficacy</strong></summary>
            <div>
                <ul><li>Locally acting secretagogue; activates type-2 chloride channels → ↑ intestinal secretion &amp; peristalsis.</li><li>Dose: 8 mcg twice daily for adult women w/ IBS-C.</li><li>Overall responder rate: 17.9% vs 10.1% placebo (P=0.0001).</li><li>NNT = 12.5.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Safety &amp; Adverse Events</strong></summary>
            <div>
                <ul><li>Most common AEs: Nausea (8-19%) &amp; diarrhea (6-14%).</li><li>Nausea may be mitigated by taking w/ food.</li><li>Overall discontinuation rates are low (1.2%).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>17. Guanylate Cyclase-C (GC-C) Activators</strong></summary>
            <div>
                <ul><li>Recommendation: Use GC-C activators to treat global IBS-C symptoms.</li><li>Strength: Strong recommendation.</li><li>Evidence Quality: High.</li></ul>
                
        <details>
            <summary><strong>Agents &amp; Mechanism</strong></summary>
            <div>
                <ul><li>Linaclotide (290 mcg daily) &amp; Plecanatide (3 mg daily).</li><li>Activate GC-C receptors → ↑ intestinal fluid secretion &amp; peristalsis.</li><li>Preclinical data suggests reduced activation of visceral nociceptive neurons.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Efficacy</strong></summary>
            <div>
                <ul><li>Linaclotide: Overall responder rate ~34%; NNT = 6.</li><li>Plecanatide: Overall responder rate ~26%; NNT = 9.</li><li>Significant separation from placebo occurs by week 1 for both agents.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Safety &amp; Adverse Events</strong></summary>
            <div>
                <ul><li>Most common AE is diarrhea.</li><li>Linaclotide: ~20% diarrhea rate; 5% withdrew due to diarrhea.</li><li>Plecanatide: ~4.3% diarrhea rate; 1.2% withdrew due to diarrhea.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>18. 5-HT4 Agonists (Tegaserod)</strong></summary>
            <div>
                <ul><li>Recommendation: Suggest use in women &lt; 65 years w/ ≤1 cardiovascular (CV) risk factor who have not adequately responded to secretagogues.</li><li>Strength: Conditional recommendation.</li><li>Evidence Quality: Low.</li></ul>
                
        <details>
            <summary><strong>Mechanism &amp; Efficacy</strong></summary>
            <div>
                <ul><li>Stimulates 5-HT4 receptor → initiates peristaltic reflex, accelerates GI transit.</li><li>Meta-analysis (11 trials): Patients on tegaserod were less likely to have persistent IBS-C symptoms vs placebo (RR 0.85; 95% CI 0.80–0.90).</li><li>Pivotal trials: 44-50% of patients on tegaserod met the primary endpoint (SGA) vs 37-39% on placebo.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Safety &amp; CV Risk</strong></summary>
            <div>
                <ul><li>Most common AE: Diarrhea (6% vs 2% placebo).</li><li>Withdrawn in 2007 due to a small excess of CV events.</li><li>Re-analysis found events occurred in patients w/ pre-existing CV risk factors.</li></ul>
                
        <details>
            <summary><strong>Current Status</strong></summary>
            <div>
                <ul><li>Re-approved in 2019 for a restricted population.</li><li>Indicated for women &lt; 65 years w/ IBS-C &amp; ≤1 CV risk factor.</li><li>Contraindicated in patients w/ &gt;1 CV risk factor.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Pharmacotherapy - IBS with Diarrhea (IBS-D)</strong></summary>
            <div>
                <ul><li>Medications specifically evaluated for IBS-D.</li></ul>
                
        <details>
            <summary><strong>19. Bile Acid Sequestrants</strong></summary>
            <div>
                <ul><li>Recommendation: Do not suggest the use of bile acid sequestrants to treat global IBS-D symptoms.</li><li>Strength: Conditional recommendation.</li><li>Evidence Quality: Very low.</li></ul>
                
        <details>
            <summary><strong>Rationale &amp; Prevalence of BAM</strong></summary>
            <div>
                <ul><li>Bile Acid Malabsorption (BAM) may cause diarrhea in a subset of IBS-D patients.</li><li>Prevalence of BAM in IBS-D based on SeHCAT testing is 28.1% (CI 22.6%–34%).</li><li>Testing for BAM (SeHCAT, serum C4) is not widely available in the US.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Evidence</strong></summary>
            <div>
                <ul><li>No placebo-controlled trials exist for global IBS-D symptoms.</li><li>One open-label study of colestipol showed 55.5% of subjects were responders.</li><li>Given lack of controlled trials, routine use is not recommended, but empiric therapy is a reasonable option if BAM is suspected.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>20. Rifaximin</strong></summary>
            <div>
                <ul><li>Recommendation: Use rifaximin to treat global IBS-D symptoms.</li><li>Strength: Strong recommendation.</li><li>Evidence Quality: Moderate.</li></ul>
                
        <details>
            <summary><strong>Mechanism &amp; Efficacy</strong></summary>
            <div>
                <ul><li>Non-absorbed antibiotic targeting an abnormal gut microbiome.</li><li>Pivotal trials: After a 2-week course, 40.8% had improvement in pain &amp; stool consistency vs 31.7% placebo.</li><li>Retreatment is safe &amp; effective for symptom recurrence (approved for up to 2 retreatments).</li><li>NNT = 9.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Safety &amp; Predictors</strong></summary>
            <div>
                <ul><li>Excellent safety profile (NNH = 8,971).</li><li>No stable bacterial resistance or significant microbiome disruption noted.</li><li>Positive lactulose breath test may predict a higher response rate (56% vs 25%).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>21. Alosetron</strong></summary>
            <div>
                <ul><li>Recommendation: Use alosetron to relieve global IBS-D symptoms in women w/ severe symptoms who have failed conventional therapy.</li><li>Strength: Conditional recommendation.</li><li>Evidence Quality: Low.</li></ul>
                
        <details>
            <summary><strong>Mechanism &amp; Efficacy</strong></summary>
            <div>
                <ul><li>5-HT3 antagonist; slows intestinal transit.</li><li>Meta-analysis: RR of symptom persistence = 0.79; NNT = 7.5.</li><li>Global symptom improvement in severe IBS-D was 12.2% to 32% greater than placebo.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Safety &amp; REMS Program</strong></summary>
            <div>
                <ul><li>Associated w/ rare but serious risk of ischemic colitis &amp; complicated constipation.</li><li>Available only under a Risk Evaluation and Mitigation Strategy (REMS) program.</li><li>Use is restricted to women w/ chronic (&gt;6 months), severe IBS-D who have failed other therapies.</li></ul>
                
        <details>
            <summary><strong>Risk Rates</strong></summary>
            <div>
                <ul><li>Post-REMS incidence of ischemic colitis: 1.03 cases/1,000 patient-years.</li><li>Constipation is the most common AE; NNH = 10.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>22. Mixed Opioid Agonists/Antagonists (Eluxadoline)</strong></summary>
            <div>
                <ul><li>Recommendation: Suggest use of mixed opioid agonists/antagonists to treat global IBS-D symptoms.</li><li>Strength: Conditional recommendation.</li><li>Evidence Quality: Moderate.</li></ul>
                
        <details>
            <summary><strong>Mechanism &amp; Efficacy</strong></summary>
            <div>
                <ul><li>Peripherally acting mixed mu- &amp; kappa-opioid agonist, delta-opioid antagonist.</li><li>Significantly improved composite endpoint of pain &amp; stool consistency vs placebo (e.g., 31.0% vs 19.5% at 26 weeks for 100mg dose).</li><li>NNT = 9-14.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Safety &amp; Contraindications</strong></summary>
            <div>
                <ul><li>Most common AE: Constipation (8%).</li><li>Serious AEs: Pancreatitis (0.4%) &amp; Sphincter of Oddi spasm (0.5%).</li><li>Contraindicated in patients w/o a gallbladder, history of pancreatitis, alcohol abuse (&gt;3 drinks/day), or severe hepatic impairment.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Central Neuromodulators &amp; Psychotherapies</strong></summary>
            <div>
                <ul><li>Interventions targeting the brain-gut axis.</li></ul>
                
        <details>
            <summary><strong>24. Gut-Directed Psychotherapies (GDPs)</strong></summary>
            <div>
                <ul><li>Recommendation: Suggest gut-directed psychotherapies be used to treat global IBS symptoms.</li><li>Strength: Conditional recommendation.</li><li>Evidence Quality: Very low.</li></ul>
                
        <details>
            <summary><strong>Rationale &amp; Types</strong></summary>
            <div>
                <ul><li>Targets cognitive-affective drivers of symptoms (e.g., pain catastrophizing, stress sensitivity).</li><li>Types include: Cognitive-Behavior Therapy (CBT), Gut-Directed Hypnotherapy (GDH), Mindfulness.</li><li>Less effective in patients w/ comorbid mental health conditions; these patients need referral to non-GI mental health professionals.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Efficacy &amp; Clinical Use</strong></summary>
            <div>
                <ul><li>Level 1 evidence shows efficacy &amp; durability, especially for CBT.</li><li>NNT = 4 (using IBS-Symptom Severity Scale).</li><li>Low risk, long-term benefits, and can be used for any IBS subtype (IBS-M, IBS-U).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Investigational &amp; Other Therapies</strong></summary>
            <div>
                <ul><li>Emerging or non-recommended therapies.</li></ul>
                
        <details>
            <summary><strong>25. Fecal Microbiota Transplant (FMT)</strong></summary>
            <div>
                <ul><li>Recommendation: Against the use of fecal transplant for the treatment of global IBS symptoms.</li><li>Strength: Strong recommendation.</li><li>Evidence Quality: Very low.</li></ul>
                
        <details>
            <summary><strong>Rationale &amp; Evidence</strong></summary>
            <div>
                <ul><li>Conceptually appealing due to the role of the microbiome in IBS.</li><li>Meta-analysis showed no significant difference in global symptoms vs placebo (RR 0.93).</li><li>Results are conflicting &amp; of very low quality.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Conclusion</strong></summary>
            <div>
                <ul><li>Cannot be recommended at present.</li><li>Requires large, well-designed, placebo-controlled trials to determine any potential role, optimal donor, and best delivery technique.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
    </div>
    
</div>


<script>
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');

    // Close all
    allDetails.forEach(detail => detail.removeAttribute('open'));

    // Open based on depth
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') depth++;
            parent = parent.parentElement;
        }
        if (depth < level) detail.setAttribute('open', '');
    });
}

// Automatically open to level 1 on page load
window.addEventListener('DOMContentLoaded', () => {
    setMindmapLevel(1);
});

function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;

    const onMouseDown = (e) => {
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };

    const elementDrag = (e) => {
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none"; // cancel centering transform
        elmnt.style.bottom = "auto"; // cancel fixed bottom
    };

    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };

    onMouseDown(event);
}
</script>


</body>
</html>
